Abstract

The molecular basis of disease progression from UV-induced precancerous actinic keratosis (AK) to malignant invasive cutaneous squamous cell carcinoma (cSCC) and potentially lethal metastatic disease remains unclear. DNA sequencing studies have revealed a massive mutational burden but have yet to illuminate mechanisms of disease progression. Here we perform RNAseq transcriptomic profiling of 110 patient samples representing normal sun-exposed skin, AK, primary and metastatic cSCC and reveal a disease continuum from a differentiated to a progenitor-like state. This is accompanied by the orchestrated suppression of master regulators of epidermal differentiation, dynamic modulation of the epidermal differentiation complex, remodelling of the immune landscape and an increase in the preponderance of tumour specific keratinocytes. Comparative systems analysis of human cSCC coupled with the generation of genetically engineered murine models reveal that combinatorial sequential inactivation of the tumour suppressor genes Tgfbr2, Trp53, and Notch1 coupled with activation of Ras signalling progressively drives cSCC progression along a differentiated to progenitor axis. Taken together we provide a comprehensive map of the cSCC disease continuum and reveal potentially actionable events that promote and accompany disease progression.

The process by which actinic keratosis differentiates to malignant invasive cutaneous squamous cell carcinoma is unclear. Here, the authors use RNA-seq to illustrate a disease continuum between the two states, and use in vivo models to confirm the role of Tgfbr2, Trp53, and Notch1 in this process.

Details

Title
Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression
Author
Bailey, Peter 1   VIAFID ORCID Logo  ; Ridgway, Rachel A. 2   VIAFID ORCID Logo  ; Cammareri, Patrizia 3 ; Treanor-Taylor, Mairi 4   VIAFID ORCID Logo  ; Bailey, Ulla-Maja 2   VIAFID ORCID Logo  ; Schoenherr, Christina 2   VIAFID ORCID Logo  ; Bone, Max 5   VIAFID ORCID Logo  ; Schreyer, Daniel 6   VIAFID ORCID Logo  ; Purdie, Karin 7 ; Thomson, Jason 8 ; Rickaby, William 9 ; Jackstadt, Rene 10 ; Campbell, Andrew D. 2   VIAFID ORCID Logo  ; Dimonitsas, Emmanouil 11 ; Stratigos, Alexander J. 11 ; Arron, Sarah T. 12   VIAFID ORCID Logo  ; Wang, Jun 7   VIAFID ORCID Logo  ; Blyth, Karen 5   VIAFID ORCID Logo  ; Proby, Charlotte M. 13   VIAFID ORCID Logo  ; Harwood, Catherine A. 8 ; Sansom, Owen J. 5   VIAFID ORCID Logo  ; Leigh, Irene M. 7   VIAFID ORCID Logo  ; Inman, Gareth J. 5   VIAFID ORCID Logo 

 University of Glasgow, School of Cancer Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X); University of Heidelberg, Department of Surgery, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373); University Clinic Heidelberg, Section Surgical Research, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908) 
 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196) 
 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); University of Edinburgh, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); University of Edinburgh, Edinburgh Medical School, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
 University of Glasgow, School of Cancer Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X); Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196) 
 University of Glasgow, School of Cancer Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X) 
 Queen Mary University of London, Faculty of Medicine and Dentistry, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133) 
 Queen Mary University of London, Faculty of Medicine and Dentistry, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133); Department of Dermatology, Royal London Hospital, Barts Health NHS Trust, London, UK (GRID:grid.416041.6) (ISNI:0000 0001 0738 5466) 
 St John’s Institute of Dermatology, St Thomas’s Hospital, London, UK (GRID:grid.425213.3) 
10  Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); German Cancer Research Centre (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584) 
11  1st Department of Dermatology and Venereology, Andreas Sygros Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece (GRID:grid.5216.0) (ISNI:0000 0001 2155 0800) 
12  University of of California at San Francisco, Department of Dermatology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
13  University of Dundee, Molecular and Clinical Medicine, School of Medicine, Dundee, UK (GRID:grid.8241.f) (ISNI:0000 0004 0397 2876) 
Pages
5211
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2857176014
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.